A clinical study of non-bioartificial liver DPMAES support system in hepatitis B-related acute-on-chronic liver failure
Open Access
- 20 January 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Abstract
This study aims to observe the clinical efficacy of the dual plasma molecular adsorption exchange system (DPMAES) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), with a focus on its regulatory effect on cytokine storm. A total of 60 HBV-ACLF patients were enrolled in this study. The observation group, comprising 30 patients, received DPMAES treatment, while the control group underwent PE treatment. We compared the efficacy changes between the two groups post-treatment. A total of 55 HBV-ACLF patients who completed the study were analyzed, Patients treated with DPMAES showed significant improvements in clinical outcomes. After DPMAES treatment, HBV-ACLF patients exhibited notably 90 day survival rate increased by 18% compared to those in the PE group. Moreover, total bilirubin levels decreased markedly, albumin and platelet levels increased compared to the PE group. After DPMAES treatment, the patient showed a significant decrease in inflammatory cytokine IL-6 (t = 5.046, P < 0.001) and a significant decrease in procalcitonin (t = 4.66, P < 0.001). DPMAES was more effective than PE in rapidly reducing TBiL, improving coagulation function and mitigating cytokine storm. It maintained platelet stability more effectively while minimizing albumin consumption to a greater extent, significantly improved 90-day survival. Trial registration: Chinese Clinical Trial Registry, ChiCTR2300076117.Keywords
Funding Information
- the Project of Science and Technology Department of Shaanxi Province (2023KJXX-111, 2021FS-233)
- The project of Ankang Science and Technology Bureau (AK2019SF-14, AK2021-SF-08)
This publication has 22 references indexed in Scilit:
- Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver FailureCells, 2020
- Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failureJournal of International Medical Research, 2020
- Therapeutic effect of double plasma molecular adsorption system and sequential half‐dose plasma exchange in patients with HBV‐related acute‐on‐chronic liver failureJournal of Clinical Apheresis, 2019
- Acute-on-Chronic Liver Failure in China: Rationale for Developing a Patient Registry and Baseline CharacteristicsAmerican Journal of Epidemiology, 2018
- [Research advances in diagnosis and treatment of liver failure in 2016].2017
- Liver Regeneration: Analysis of the Main Relevant Signaling MoleculesMediators of Inflammation, 2017
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014Hepatology International, 2014
- Interleukin‐21 is upregulated in hepatitis B‐related acute‐on‐chronic liver failure and associated with severity of liver diseaseJournal of Viral Hepatitis, 2011
- Artificial Liver Support System in China: A Review Over the Last 30 YearsTherapeutic Apheresis and Dialysis, 2006
- Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repairHepatology, 2006